Duavee and Trazodone Interaction: What Women Need to Know

What Is Duavee and Why Do Postmenopausal Women Take It?

Duavee is a fixed-dose combination of conjugated estrogens 0.45 mg and bazedoxifene 20 mg, taken once daily by mouth. It is FDA-approved for two indications in postmenopausal women who still have their uterus: moderate-to-severe vasomotor symptoms (hot flashes, night sweats), and prevention of postmenopausal osteoporosis.

Bazedoxifene acts as a selective estrogen receptor modulator (SERM). Its job is to protect the uterine lining from the proliferative effect of the conjugated estrogens, removing the need for a separate progestogen. That is the design feature that makes Duavee different from conventional estrogen-plus-progestogen hormone therapy.

Who Is the Typical Duavee Patient?

Most women prescribed Duavee are in early-to-mid postmenopause, typically between ages 50 and 65, who have moderate-to-severe vasomotor symptoms and intact uterine anatomy. The SMART-1 trial (Selective estrogens, Menopause And Response to Therapy) enrolled 3,397 postmenopausal women and confirmed that the combination reduced mean hot flash frequency by approximately 74 percent versus placebo after 12 weeks, a result that drove FDA approval.

Women in this life stage also have high rates of depression, anxiety, and sleep disruption. That is exactly why trazodone prescriptions overlap with Duavee use.

Trazodone in Postmenopausal Women

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved for major depressive disorder, but it is prescribed far more often at low doses (25-100 mg at bedtime) for insomnia. Approximately 40-60 percent of perimenopausal and postmenopausal women report significant sleep disturbance, making low-dose trazodone one of the most commonly reached-for off-label sleep aids in this population. Knowing how it interacts with Duavee is not academic. It is a daily clinical question.

The Pharmacokinetic Interaction: CYP3A4 Is the Key Enzyme

The most mechanistically important interaction between Duavee and trazodone is pharmacokinetic, mediated primarily through CYP3A4.

How Bazedoxifene Is Metabolized

Bazedoxifene undergoes extensive glucuronidation via UGT1A enzymes in the gut wall and liver, but CYP3A4 also contributes to its oxidative metabolism. The FDA label for Duavee notes that co-administration with strong CYP3A4 inhibitors (such as ketoconazole 400 mg daily for seven days) increased bazedoxifene peak plasma concentration (Cmax) by approximately 1.4-fold and area under the curve (AUC) by approximately 1.5-fold. That is a moderate increase, not a dramatic one, but it sets the ceiling for what CYP3A4 interactions can do to bazedoxifene exposure.

Where Trazodone Fits Into the CYP Picture

Trazodone is primarily metabolized by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP). In that role trazodone acts as a CYP3A4 substrate, not a strong inhibitor. However, at higher doses trazodone shows weak-to-moderate CYP3A4 inhibitory properties, as described in the trazodone FDA prescribing information. Two CYP3A4 substrates competing for the same enzyme can each raise the other's plasma levels modestly through competitive inhibition, even when neither drug is a dedicated inhibitor.

The practical result: when trazodone is co-prescribed with Duavee, bazedoxifene plasma concentrations may rise slightly above expected levels, and trazodone concentrations may do the same. Neither shift is expected to be dramatic at standard doses, but women who are CYP3A4 poor metabolizers by genotype, or who are also taking other CYP3A4 interactors (fluconazole, clarithromycin, grapefruit in large quantities), face additive competitive pressure on the same metabolic pathway.

Conjugated Estrogens and CYP3A4

The estrogen component of Duavee is similarly metabolized through CYP3A4 and CYP1A2. A 2001 pharmacokinetic study in postmenopausal women confirmed that CYP3A4 inhibitors raise estrone and equilin sulfate levels significantly. With trazodone, the estrogen-side effect is likely small, but estrogen exposure is relevant in postmenopausal women because even small excess can affect breast tissue density and endometrial safety signals over years of use.

The Pharmacodynamic Interaction: Additive Sedation and Fall Risk

The second layer of this interaction is pharmacodynamic. Both drugs cause CNS sedation, and their effects add together.

Trazodone's Sedation Mechanism

Trazodone produces sedation primarily through histamine H1 receptor antagonism and alpha-1 adrenergic blockade, not through its serotonergic action. At the low doses used for sleep (25-100 mg), sedation is the dominant effect. A 2017 meta-analysis in Sleep Medicine Reviews found that trazodone at 50-100 mg significantly reduced sleep-onset latency and improved sleep continuity in adults with primary insomnia, but residual daytime sedation affected 15-20 percent of users.

Does Duavee Contribute to Sedation?

Duavee itself is not sedating by mechanism. The conjugated estrogens may actually have mild sleep-promoting effects through progesterone-independent pathways, but bazedoxifene does not directly cause CNS depression. The concern is indirect: if bazedoxifene plasma levels rise because of CYP3A4 competition, and if the estrogen component contributes to mild fluid retention or cardiovascular changes that affect sleep architecture, the net sedation burden the woman experiences at night comes mainly from trazodone. Duavee's role in the sedation equation is to raise trazodone exposure slightly rather than to add its own sedative effect.

Fall Risk in Postmenopausal Women

This matters practically because postmenopausal women are already at higher baseline fall risk from reduced proprioception, lower muscle mass, and orthostatic changes. The CDC estimates that one in four women over age 65 falls each year, and drug-induced sedation is a modifiable contributor. Trazodone, particularly at doses above 100 mg, causes orthostatic hypotension through alpha-1 blockade. Adding even modest trazodone concentration increases via CYP3A4 competition could tip a woman who is borderline into symptomatic orthostasis when she gets up at night.

A practical risk-stratification framework for women combining Duavee and trazodone:

| Risk Level | Profile | Recommended Action | |---|---|---| | Low | Age <65, no concurrent CYP3A4 interactors, trazodone dose <100 mg at bedtime | Standard monitoring, counseling on morning sedation | | Moderate | Age 65-75, one additional CYP3A4 substrate, trazodone 100-200 mg | Check standing blood pressure at follow-up, consider dose timing separation | | Higher | Age >75, polypharmacy, CYP3A4 inhibitor co-prescribed, trazodone >200 mg | Review necessity of both drugs, consider fall-risk assessment tool |

Severity Classification and Clinical Databases

Drug-drug interaction databases do not all classify the Duavee/trazodone pair identically, because the combination has not been studied in a dedicated clinical trial. The interaction is inferred from known metabolic profiles of each drug.

Lexicomp rates the bazedoxifene/trazodone combination as a moderate interaction warranting clinical monitoring. Micromedex places it in a similar tier. Neither database calls for an absolute contraindication. The absence of a dedicated DDI trial in postmenopausal women is an evidence gap worth naming plainly: the safety signal is extrapolated from metabolic pathway data, not from a controlled clinical study of women taking both drugs simultaneously.

Women have historically been under-represented in pharmacokinetic DDI studies. The trazodone trials that establish its CYP3A4 profile were conducted predominantly in adult mixed-sex populations, and the Duavee pharmacokinetic studies (required by FDA) were conducted in postmenopausal women, but without trazodone as a co-interactor. That gap means real-world experience from clinicians who manage postmenopausal women on both drugs is currently the best evidence available.

Who Should and Should Not Combine These Drugs

Women Who May Be Reasonable Candidates

You may be a reasonable candidate for concurrent Duavee and trazodone use if you:

• Are in early postmenopause (under age 65) with significant vasomotor symptoms and sleep disruption
• Need low-dose trazodone (25-50 mg at bedtime) specifically for sleep-onset difficulty
• Are not taking other CYP3A4 inhibitors (no azole antifungals, no macrolide antibiotics regularly, no grapefruit daily)
• Have normal standing blood pressure without orthostatic symptoms
• Have had a bone mineral density scan confirming you are a candidate for Duavee's osteoporosis-prevention indication

Women Who Should Reconsider the Combination

You should discuss alternatives with your clinician if you:

• Are over age 75, where polypharmacy and fall risk are more pressing
• Take other CYP3A4 interactors (fluconazole, clarithromycin, certain HIV antiretrovirals, or verapamil)
• Need trazodone at doses above 150 mg for depression management, where the pharmacokinetic interaction becomes more clinically significant
• Have pre-existing orthostatic hypotension or a history of falls
• Have cardiovascular disease where even modest estrogen-level fluctuation warrants tighter monitoring

For postmenopausal women with depression who need both antidepressant efficacy and sleep improvement, an alternative antidepressant with a cleaner CYP profile relative to Duavee (such as escitalopram, which is primarily CYP2C19-mediated) may be worth discussing with your prescriber.

Dose Timing, Monitoring, and Practical Counseling

Timing the Doses

Separating the doses by time does not eliminate the pharmacokinetic interaction, because CYP3A4 competition operates across the dosing interval rather than only at the moment of co-administration. Both drugs reach peak concentration within two to four hours of ingestion. Taking Duavee in the morning and trazodone at bedtime (a common real-world pattern) creates roughly twelve hours of separation at peak, which reduces, though does not eliminate, competition at the enzyme level. This timing strategy is clinically reasonable and worth recommending.

Duavee should be taken once daily without regard to food, per the FDA label. Trazodone for sleep is taken 30-60 minutes before bedtime, often with a light snack to reduce dizziness.

What Your Clinician Should Monitor

1. Daytime sedation at the first follow-up (four to six weeks after starting both drugs together). Ask specifically whether you feel groggy in the morning or have reduced alertness while driving.
2. Orthostatic blood pressure (measured seated then standing after two minutes) if trazodone dose exceeds 100 mg or if you report lightheadedness.
3. Vaginal bleeding or spotting. Because bazedoxifene is the uterine protector in Duavee, any unexpected breakthrough bleeding requires evaluation to confirm that the endometrial protection is intact, particularly if CYP3A4 competition has shifted bazedoxifene exposure patterns.
4. Bone density at baseline and at one to two years, as recommended for the osteoporosis-prevention indication by The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy.
5. Breast symptoms. Slightly elevated estrogen exposure over time is a biologically plausible consequence of this interaction. Annual breast exam and adherence to mammography screening guidelines per ACOG Practice Bulletin 179 remain important.

Patient Counseling Points

Tell your prescriber about every supplement and herbal product you take. St. John's Wort is a potent CYP3A4 inducer and will lower bazedoxifene levels, potentially removing its uterine protective effect. The Duavee FDA label explicitly warns against concurrent St. John's Wort use.

Do not take calcium supplements within two hours of Duavee, as calcium can reduce estrogen absorption. Trazodone's absorption is not significantly affected by calcium, so spacing these apart works in practice.

Alcohol amplifies trazodone's sedation and orthostatic hypotension. Postmenopausal women on both Duavee and trazodone who also drink alcohol face a compounded fall risk at night.

Pregnancy, Lactation, and Contraception

Duavee is contraindicated in pregnancy. The FDA label carries a black box warning equivalent for use in pregnancy: conjugated estrogens/bazedoxifene must not be used during pregnancy because estrogen exposure in pregnancy is associated with fetal harm, and bazedoxifene, as a SERM, has theoretical teratogenic potential based on animal reproductive studies.

Duavee is indicated only for postmenopausal women. By definition, pregnancy should not be expected in this population. However, women in perimenopause who are prescribed Duavee off-label (which does happen clinically) must use reliable contraception if any chance of pregnancy remains. Perimenopausal women can and do conceive: ovulation occurs unpredictably until menopause is confirmed by 12 consecutive months of amenorrhea, so contraception cannot be abandoned simply because cycles are irregular.

Trazodone in pregnancy is classified as FDA Pregnancy Category C (old system) or under current labeling: no adequate and well-controlled studies in pregnant women, animal studies show adverse effects. A 2020 JAMA Psychiatry analysis found modest associations between prenatal antidepressant exposure and neonatal adaptation syndrome, though causality remains debated. Trazodone should not be used in pregnancy without careful risk-benefit discussion with a maternal-fetal medicine specialist.

Lactation. Conjugated estrogens reduce milk production and are not recommended during breastfeeding. Bazedoxifene transfer into human breast milk has not been studied adequately. Trazodone does transfer into breast milk at low levels; a case series reported infant trazodone concentrations at approximately 1 percent of the maternal weight-adjusted dose, which is below the threshold typically considered concerning (10 percent), but data are sparse. Neither drug combination is considered appropriate during active lactation.

Contraception requirement. Women in late perimenopause who are prescribed Duavee for vasomotor symptoms should use a non-hormonal contraceptive method (copper IUD, condoms) because Duavee's estrogen-SERM design was studied in confirmed postmenopausal women, not in ovulatory women who might conceive. Hormonal contraceptives would compete with bazedoxifene at the estrogen receptor and alter the risk-benefit balance of the combination.

Other Duavee Drug Interactions Relevant to Postmenopausal Women

Trazodone is not Duavee's only interaction partner. Understanding the full interaction picture helps you and your prescriber make safe choices.

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): raise bazedoxifene AUC by up to 50 percent per the Duavee label. Avoid or monitor closely.
• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort): lower bazedoxifene exposure, risking loss of uterine protection. Avoid.
• Thyroid hormone (levothyroxine): estrogens increase thyroid-binding globulin, raising total T4 and T3 levels without changing free thyroid hormone in most women. However, women with hypothyroidism on levothyroxine may need a dose increase when starting any estrogen. ACOG recommends checking TSH six to eight weeks after initiating or changing estrogen therapy in women on thyroid replacement.
• Cholesterol-lowering statins (many are CYP3A4 substrates): simvastatin and atorvastatin may see modest concentration increases. This is relevant because postmenopausal women are frequently on both hormone therapy and statins for cardiovascular risk management.
• Benzodiazepines and sleep aids (alprazolam, zolpidem): additive sedation on top of trazodone creates a three-way CNS depressant burden. The Duavee/trazodone/benzodiazepine combination should generally be avoided in women over 65.

The Evidence Gap: What We Don&apos;t Know

No published randomized controlled trial has studied the Duavee and trazodone combination directly in postmenopausal women. The interaction assessment relies on three pillars: the known CYP3A4 profiles of each drug, the FDA-commissioned pharmacokinetic studies that quantified bazedoxifene's sensitivity to CYP3A4 perturbation, and clinical reasoning about pharmacodynamic sedation overlap.

A direct DDI trial in postmenopausal women would ideally measure bazedoxifene AUC and Cmax with and without steady-state trazodone, measure trazodone and mCPP plasma concentrations with and without Duavee, and assess sedation, orthostatic blood pressure, and bone marker changes over 12 weeks. That trial has not been done. Until it is, clinicians must extrapolate, and women deserve to know that the guidance is extrapolated.

The Menopause Society 2023 hormone therapy position statement does not specifically address trazodone co-administration, reflecting this evidence gap. The statement does note, as a general principle, that "the benefits of hormone therapy outweigh the risks for most healthy women within 10 years of menopause onset," and that individualized risk-benefit conversations are essential when co-medications are involved.